Cell therapy · developed by Nanjing Legend Biotech
LUCAR-G79D is a T-cell therapy given by infusion after a conditioning regimen of cyclophosphamide and fludarabine. It is studied in systemic lupus erythematosus and idiopathic inflammatory myopathies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07331272 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Recruiting | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Inflammatory Myopathies(IIM)Systemic Lupus Erythematosus (SLE)
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →